drugset / Trial / NCT02846675

Safety and Efficacy of Autologous SVF Cells in Treating Patients With Osteoarthritis

NCT02846675

Phase 1/2 Completed 50 enrolled Shanghai East Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

it's a self-control, double blind study of autologous adipose-derived stromal vascular fraction (SVF) to treat 50 osteoarthritic knees of grade II or III (K-L scale) under IRB-approved protocol in a feasibility and safety study.

Timeline

Start
2014-11-01
Primary completion
2017-07-31
Completion
2018-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy 5e+07 cells Other

Indications